Abstract 183P
Background
In Asia, the standard treatment for locally advanced gastric cancer (LAGC) involves gastrectomy with D2 dissection and adjuvant chemotherapy. However, achieving adequate chemotherapy intensity after gastrectomy presents challenges. Previous trials have shown the effectiveness of neoadjuvant chemotherapy (NAC). Nevertheless, limited research has been conducted to explore the feasibility of NAC-SOX for older patients with LAGC. This phase II study (KSCC1801) aimed to assess the safety and efficacy of NAC-SOX in LAGC patients aged ≥ 70 years. Herein, we present the conclusive data analysis of KSCC1801, shedding light on its outcomes.
Methods
Patients received NAC consisting of three cycles of SOX130 (oxaliplatin 130 mg/m2 on day 1, oral S-1 40-60 mg twice daily for two weeks every three weeks), followed by gastrectomy with lymph node dissection. The primary endpoint was the dose intensity (DI) of the treatment. Secondary endpoints included safety, R0 resection rate, pathological response rate (pRR), overall survival, and relapse-free survival.
Results
The study enrolled 26 patients with a median age of 74.5 years. The median DI in the NAC-SOX130 treatment was 97.2% for S-1 and 98.3% for oxaliplatin. NAC was successfully administered to 25 patients (96.2%), among whom 24 (92.3%) underwent gastrectomy with lymphadenectomy. The R0 resection rate was 92.3%, and the pRR (≥ grade 1b) was 62.5%. Major adverse events (≥ grade 3) included neutropenia (20.0%), thrombocytopenia (11.5%), anorexia (11.5%), nausea (7.7%), and hyponatremia (7.7%). Postoperative complications such as abdominal infection, elevated blood amylase, and bacteremia occurred in one patient each. The 1- and 2-year OS rates were 93.3% and 89.7%, respectively. The 1- and 2-year RFS rates were 68.7% and 58.6%, respectively.
Conclusions
NAC-SOX130 proves to be a feasible therapy for older patients aged ≥ 70 years.
Clinical trial identification
jRCTs071180001.
Editorial acknowledgement
Legal entity responsible for the study
KSCC (Kyushu Study group of Clinical Cancer).
Funding
Yakult Honsha.
Disclosure
E. Oki: Financial Interests, Personal, Invited Speaker: Taiho Pharmaceutical Co. Ltd., Ono Pharmaceutical Co. Ltd., Chugai Pharmaceutical Co. Ltd., Bayer, Eli Lilly, Bristol-myers Squibbb, MSD; Financial Interests, Personal and Institutional, Research Grant: Guardant Health. All other authors have declared no conflicts of interest.
Resources from the same session
122P - Distinct transcriptomic immune profiling and clinicopathological features of cribriform morphology in colorectal adenocarcinomas
Presenter: Abdelhakim Khellaf
Session: Poster Display
Resources:
Abstract
123P - Spatial molecular profiling identifies FGF20 upregulation on cancer-associated fibroblast and FGFR2-PI3K/Akt activation in tumor cells of sporadic early-onset colon cancer
Presenter: Dave Hoon
Session: Poster Display
Resources:
Abstract
124P - Characteristics, prognosis and therapeutic effects of non-V600 BRAF mutated colorectal cancer
Presenter: Lalida Arsa
Session: Poster Display
Resources:
Abstract
125P - Final results of APOLLON-11 and SOYUZ-APOLLON study: Multicentre prospective observational post-authorization study of bevacizumab biosimilar in patients with metastatic colorectal cancer in real-world practice
Presenter: Alexey Tryakin
Session: Poster Display
Resources:
Abstract
126P - From tumor height (TH) to tumor regression grade (TRG) in locally advanced rectal cancers (LARC) during total neadjuvant therapy (TNT): A retrospective analysis
Presenter: Valeria Pusceddu
Session: Poster Display
Resources:
Abstract
127P - A meta-analysis of efficacy and safety from head-to-head first-line (1L) trials of epidermal growth factor receptor inhibitors (EGFRIs) versus bevacizumab in combination with chemotherapy (CT) doublets in patients with RAS wild-type (WT) metastatic colorectal cancer (mCRC) by sidedness
Presenter: Takayuki Yoshino
Session: Poster Display
Resources:
Abstract
128TiP - A phase II study of cadonilimab + FOLFOXIRI and bevacizumab as initial therapy for unresectable proficient mismatch repair/microsatellite stable (pMMR/MSS) metastatic colorectal cancer (mCRC)
Presenter: Rongbo Lin
Session: Poster Display
Resources:
Abstract
140P - Prevalence of claudin-18 isoform 2 (CLDN18.2) positivity in locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mg/GEJ) adenocarcinoma in patients (pts) in the Asia region: Phase III SPOTLIGHT and GLOW studies
Presenter: Hoo Hwoei Fen Soo
Session: Poster Display
Resources:
Abstract
141P - Early phase trials outcomes in refractory upper GI cancers: A 10-year analysis from the SCRI UK phase I unit
Presenter: Antonella Cammarota
Session: Poster Display
Resources:
Abstract
142P - The survival impact of the addition of durvalumab to cisplatin/gemcitabine in advanced biliary tract cancer: A real-world, retrospective, multicentric study
Presenter: Silvia Foti
Session: Poster Display
Resources:
Abstract